Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation’ Category

Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

Posted in BioTechnology - Venture Creation, Innovations, Intellectual Property, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough on July 22, 2019| Leave a Comment »


Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

 

Reporter: Aviva Lev-Ari, PhD, RN, Berkeley PhD’83

 

for @Berkeley Alumna Ecosystem Evangelist see

https://pharmaceuticalintelligence.com/2019-vista/executive-summary/

The University of California at Berkeley appointed professor Richard Lyons as the university’s first-ever chief innovation and entrepreneurship officer (CIEO).

The Selection Process

Professor Richard Lyons was selected for the CIEO position through a rigorous recruitment and selection process that attracted several hundred top-notch applications from all over the world. Throughout the process, Lyons stood out as a true visionary, a strategic leader and an ecosystem evangelist who could understand and activate the untapped potential of Berkeley’s innovation and entrepreneurship landscape.

 

“If together we can improve the transformation of Berkeley’s prodigious intellectual product, across the whole campus, into greater societal benefit, then we will have achieved a great deal,” said Lyons, in a statement.

Image Source: Courtesy of University of California, Berkeley, Doe Library Building with the  Campanile Tower in the background

Professor Richard Lyons,  Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

  • He helped launch the Management, Entrepreneurship, & Technology (M.E.T.) dual-degree program in partnership with the College of Engineering.
  • He also initiated the Biology + Business dual degree program with Molecular & Cell Biology and
  • He revitalized the Berkeley-Haas Entrepreneurship Program (BHEP).
  • He helped the campus to launch the Berkeley SkyDeck startup accelerator in 2012 and served on its Governing Board, did that in collaboration with leadership in the Office of Research and College of Engineering.

 

SOURCE

https://venturebeat-com.cdn.ampproject.org/c/s/venturebeat.com/2019/07/10/richard-lyons-will-be-uc-berkeleys-first-ever-chief-innovation-and-entrepreneurship-officer/amp/

Advertisements

Read Full Post »

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

Posted in BioTechnology - Venture Creation, CRISPR/Cas9 & Gene Editing on June 13, 2019| 1 Comment »


Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery

 

Reporter: Aviva Lev-Ari, PhD, RN

 

GlaxoSmithKline, UC’s Doudna Establish $67M Genomics, CRISPR Research Lab

Jun 13, 2019   |  staff reporter

Save for later

 

NEW YORK (GenomeWeb) – Drug company GlaxoSmithKline announced today that it will establish a laboratory for CRISPR technologies as part of a five-year collaboration with University of California researchers.

The new Laboratory for Genomics Research (LGR) will investigate disease-causing gene mutations and develop new technologies using CRISPR to accelerate the discovery of new drugs, with a focus on immunology, oncology, and neuroscience. The LGR will receive up to $67 million in funding over the five-year collaboration period, including facilities for 24 full-time university employees funded by GSK, plus up to 14 full-time GSK employees, the company said. GSK’s artificial intelligence and machine learning group will also aid in building any necessary bioinformatics pipelines. The laboratory will be based near the University of California, San Francisco’s Mission Bay campus.

The LGR aims to automate existing CRISPR approaches so that this work can be done at scale. Ultimately, the lab’s goal is to deepen researchers’ understanding of genetics and discover new drug targets. They’re also aiming to create next-generation technologies for the pharmaceutical industry, GSK added.

The LGR will also serve as a resource for investigators at both UCSF and the University of California, Berkeley who can access and use its technology to answer their own research questions and to develop new tools.

The LGR was developed by Berkeley professor and CRISPR expert Jennifer Doudna, UCSF Professor Jonathan Weissman, and GSK CSO and President of R&D Hal Barron.

“Over the last seven years, CRISPR has transformed academic research, but until the LGR, we haven’t had a focused effort to catalyze the kind of research we know will lead to new innovation using this CRISPR tool,” Doudna said in a statement. “LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. I think we’re going to be able to do science that none of us can even imagine today.”

The collaboration will be governed by a Joint Steering Committee with equitable UC and GSK representation, with additional joint sub-committees covering patents, scientific, and project management, GSK noted. Doudna and Weissman will sit on the committee along with GSK’s new head of functional genomics, Chris Miller.

“One of our key goals is to advance the field overall and make these tools as broadly available as possible,” Weissman added in the statement. “The LGR screening center will enable labs at UCSF and Berkeley, and having access to it will give our scientists opportunities to advance their research in ways that would be very hard for them to do in their own labs.”

 

ADDITIONAL ARTICLES in GenomeWeb

SOURCE

https://www.genomeweb.com/business-news/glaxosmithkline-ucs-doudna-establish-67m-genomics-crispr-research-lab#.XQKQ8tNKgcg

 

Other related articles published in this Open Access Online Scientific Journal include the following 156 articles:

https://pharmaceuticalintelligence.com/?s=CRISPR

 

 

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: Falling in Love with Science: Championing Science for Everyone, Everywhere

Posted in Conference Coverage with Social Media, Foundations for supporting Science and Education, Open Access Journals, Philanthropy to Academic Institution, Scientific & Biotech Conferences: Press Coverage, Scientific Publishing, Scientist: Career considerations, Women in Life Sciences, tagged , , , , , , on June 4, 2019| Leave a Comment »


Falling in Love with Science: Championing Science for Everyone, Everywhere June 4 2019

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Speakers
Seema: We need to solve the problem of the lack of trust in scientists.  Some of JNJ winners of their acheivement program went on to become Nobel Laureates.   Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones.  Many diseases occur because of protein misfolding like neuro-degenerative diseases.
Seema:  Great science going on in Africa.  JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).
Dr. Horwich: got interested in science early on.  Worked on N terminal mitochondrial signal peptides.  also then got interested in how proteins fold and unfold and refold since the 1950s.  He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.
Emily Wang:  Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people.  If passionate and have a great mentor then can get a foot in the door.  Worked at Stanford in the lab.
Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this.  In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar.  He takes the word translational research very seriously.  Can you say in one sentence how this will help patients in three years?
There are multitude ways of love for science.
Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time.  Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship.  We need to use technology to disrupt and innovate.
Nsikin:  A lot of mentors nurture curiosity.  People like to see them in that story of curiosity.  That is how is bases the PBS science videos: did  a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest).  The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Foundations for supporting Science and Education, Pharmaceutical Drug Discovery, Scientific & Biotech Conferences: Press Coverage, Venture Capital, tagged , , , , , , on June 4, 2019| Leave a Comment »


Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

There is $200B in Global Investment in the Biopharmaceutical Sector Each Year. Who’s Getting It and Why?

115A, Level 100

Speakers
Each country have their own needs and most important drug cost structure. Must involve patients and providers.
BCI survey: countries output different, who improved who didnt
Is industry having collaboration with government? hardly ten percent by survey and worse vice versa
Transparancy and holistic view important for collaboration
Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments
Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance
Pitts: we need trust; staff that country offices with people who know that country. Price not defining value
Columbia:  need to attract investors

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Monoclonal Immunotherapy, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, tagged , , , , on June 3, 2019| Leave a Comment »


Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

Speakers
responsible for VC at Pfizer
developing therapeutics based on GI microbiome to treat CNS
Xontogeny is an incubator
Focusing on building their tech platforms
Results from Clarivate
In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases.  US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.
Preclinical is very strong for US VC but China VC is focused on clinical.  First time this year we see US series A break above 100.  But ex US the series A is going down.  Although preclinical deals in US is coming back not like as good as in 2006.  But alot of > 1 billion $ deals.  Most of money into mAbs and protein therapy;  antisense is big and cell therapy is big too; small molecule not as much
ClearView Healthcare
Which innovation classes attracted VC in 2018?
  • Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
  • therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs.  Nucleic Acid tech and antibody tech is high need platforms.  Startups can win by developing a strong platform not just a drug
There are pros and cons of developing a platform company versus a focused company.  Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company.  Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps.  They believe buy the therapy and only rent the platform.
Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms.  they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.
At Celgene they were solely focused on approvals not platforms.  Alot of money is required to get these platforms to market.  Concentration for platform companies should be the VCs not partnering or getting bought out by pharma.  it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money).  However it seems they (big pharma) are indicating that money is drying up or at least expect it too.
At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.
At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM.  There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »

Real Time Coverage of BIO International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA

Posted in Alzheimer's Disease, Big Data, Bio Instrumentation in Experimental Life Sciences Research, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, FDA, FDA Regulatory Affairs, Foundations for supporting Science and Education, Health Economics and Outcomes Research, Healthcare costs and reimbursement, Institutional Capital Raised by Female Founders, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Pharmaceutical Analytics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Trends in Global Economy, Venture Capital, tagged , , , , , , , , , , , on May 31, 2019| Leave a Comment »


Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.

 

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 

Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall

 

ALSO SUPERSESSIONS including:

Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth

 

See here for full AGENDA

Link for Registration: https://convention.bio.org/register/

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.

 

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at https://pharmaceuticalintelligence.com/press-coverage/

 

Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

Read Full Post »

CytoReason is re-defining the Context of the Immune System for Drug Discovery

Posted in Adaptive Immune Response to Biomaterials and Tissue Repair, BioTechnology - Venture Creation, Engineering Better T Cells, Immune Engineering, Immune Modulatory, Immunodiagnostics, Immunotherapy, NK Cell-Based Cancer Immunotherapy, Protection Against Autoimmune Disease, Synergistic Innate and Adaptive Immunotherapy on May 21, 2019| Leave a Comment »


CytoReason is re-defining the Context of the Immune System for Drug Discovery

Reporter: Aviva Lev-Ari, PhD, RN

 

CytoReason is re-defining the context of the immune system at a cellular level in order to better understand disease and support more effective drug discovery and development.

Our leading-edge machine-learning driven approach identifies “cause and effect” of the gene/cell/cytokine relationships that lie at the heart of treating disease.

Faster and more accurately than ever before.

CytoReason’s mission is to simulate the cells that can stimulate discovery of:​

  • New targets for treating disease
  • New insights to mechanism of actions (both of disease and drugs)
  • Differences in responses to both disease and treatment
  • Which diseases a drug can impact

We have developed a unique machine-learning driven approach to “seeing” the cells that can make the difference in patients seeing a better life.

The insights our approach generates, enable pharmaceutical and biotech companies to make the right decisions, at the right time, in the drug discovery and development programs that bring better therapies.

Based on cutting edge technologies, trained on data that would normally be impossible to access, and steered by leading biological and data science researchers, our approach is underpinned by three core principles:​

SOURCE

https://www.cytoreason.com/

Press Release

https://docs.wixstatic.com/ugd/216dd2_b715f2c29a8c496eb65315d332a7077e.pdf

Case Studies

Click one of the buttons below to view a short case study presention:

Collaboration & Results

Working with leading global pharma and biotech companies and key research institutions, our results help guide R&D decision making.

​

​

​

​

​

​

Results

Our platform is tried and tested, producing real results with validation

•    Discovered: New cellular players in melanoma microenvironment

•    Discovered: New IL4 mechanism of action in atopic dermatitis

•    Discovered: Novel pre-treatment biomarkers in IBD anti-TNFα therapy

•    Discovered: 355 previously unreported cell/cytokine interactions (view infographic)

Publications

Science is the backbone of our methodologies and applications, and must stand the test of scientific scrutiny.  To date we have 16 research papers published in top quality peer-reviewed scientific journals, including four in 2018 alone – 3 of which were published in journals from the Nature group

SOURCE

 

Shen-Orr told Forbes in an article published late last month that CytoReason’s tech is able to calculate immune age in one of two ways: “Via cell-subset composition nearest neighbor approach or based on a gene expression signature where the genes are predictive of the cell-subsets composition, and they test for their enrichment in the gene expression pattern of the sample. The immune profiles of individuals are used to predict immune changes based on a machine learning methodology deployed on data on a range of cell-subsets. ”

“The immune age is a biological clock that will help to identify, the decline and progress in immunity that occurs in old age, to determine preventive measures and develop new treatment modalities to minimize chronic disease and death,” he added.

CytoReason’s tech has so far yielded two pending patents, 10 commercial and scientific collaborations, and 16 peer-reviewed publications.

Harel says it was a combination of forces that made CytoReason’s immune-focused methodology work: Big Data, machine learning, and biology. He describes it as “the intersection of computer science and biology.”

SEE ALSO: The Future Of Medicine: Israeli Scientists Unveil New Tech To 3D-Print Personalized Drugs

 

Professor Magdassi tells NoCamels that with 3D printing of hydrogels, molecules that are soluble in water, scientists can improve the performance of the drug through its delivery. For example, “the hydrogel once ingested can be designed to swell, releasing two, or three, or four drugs at a time [or with a delay] or it can be designed not to swell, depending on what we are trying to achieve.”

“The drug can be tailored to the patient because of the unique shape or structure of the hydrogel and/or its release behavior,” Professor Magdassi explains.

Currently, there is one 3D-printed drug on the market. In 2015, the US Food and Drug Administration (FDA) approved Spritam, a 3D-printed powdered drug in pill form for the treatment of epileptic seizures, designed to dissolve faster than other pills.

SOURCE

http://nocamels.com/2018/11/future-medicine-israel-3d-print-personalized-drugs/

 

Quantifying The Age Of Our Immune System Could Bring Us Some Steps Closer To Precision Medicine

Yiannis Mouratidis

Contributor

Science

Last January, CytoReason announced an agreement with Pfizer, in which the latter will leverage the former’s technology to create cell-based models of the immune system. According to the agreement, CytoReason will receive an undisclosed amount in the low double-digit millions of U.S. dollars from Pfizer in access fees, research support and success-based payments. Prof. Shen-Orr concluded, “The immune age is a biological clock that will help to identify, the decline and progress in immunity that occurs in old age, to determine preventive measures and develop new treatment modalities to minimize chronic disease and death.”
SOURCE

Read Full Post »

Older Posts »